Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $1.15 USD
Change Today +0.0099 / 0.87%
Volume 299.3K
COCP On Other Exchanges
As of 8:10 PM 05/26/15 All times are local (Market data is delayed by at least 15 minutes).

cocrystal pharma inc (COCP) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/31/15 - $1.53
52 Week Low
08/5/14 - $0.25
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for COCRYSTAL PHARMA INC (COCP)

Related News

No related news articles were found.

cocrystal pharma inc (COCP) Related Businessweek News

No Related Businessweek News Found

cocrystal pharma inc (COCP) Details

Cocrystal Pharma, Inc., a preclinical-stage biopharmaceutical company, intends to develop medicines for use in treating human viral diseases. The company focuses on developing inhibitors that viral replication enzymes and viral replication protein. It is developing antiviral therapeutics for human diseases, including Hepatitis C virus, Influenza virus, and Norovirus. The company also develops targeted in-house chemical libraries consisting of antiviral compounds of nucleosides, non-nucleoside inhibitors, metal-binding inhibitors, and fragments. In addition, it is developing compounds that inhibit HCV helicase, an enzyme that is essential for hepatitis C viral replication. The company was founded in 2007 and is headquartered in Bothell, Washington.

22 Employees
Last Reported Date: 03/31/15
Founded in 2007

cocrystal pharma inc (COCP) Top Compensated Officers

Co-Founder and President
Total Annual Compensation: $180.0K
Co-Founder, Vice Chairman, Senior Advisor and...
Total Annual Compensation: $250.0K
Chief Financial Officer , Principal Accountin...
Total Annual Compensation: $150.0K
Compensation as of Fiscal Year 2014.

cocrystal pharma inc (COCP) Key Developments

Cocrystal Pharma, Inc. Expects to Begin Clinical Studies on Several of its Antiviral Therapeutic Treatments in 2015

Cocrystal Pharma, Inc. expected to begin clinical studies on several of its antiviral therapeutic treatments in 2015. The company has several drugs in various stages of development for the treatment of Hepatitis C, Influenza, Norovirus, Dengue Fever and others. The company is backed by Opko Health, who currently has an 8% stake in the company. This relationship should be beneficial for COCP as they work to streamline their products into clinical studies.

Cocrystal Pharma, Inc. Announces Executive Changes

Cocrystal Pharma, Inc. announced that due to medical reasons, Dr. Gary Wilcox will step down as the current Chief Executive Officer. Mr. Jeffrey Meckler has been appointed as the Interim Chief Executive Officer of the Company effective with the filing of the Form 10-K, later this month. Dr. Wilcox will become the Vice Chairman of the Board of Directors and continue as a senior advisor to the company. Mr. Meckler will continue as a Director of the Company, and Dr. Raymond F. Schinazi will become the Chairman of the Board. Mr. Meckler has over 25 years of experience in life science companies including 17 years at Pfizer Inc. in a variety of positions, including Manufacturing, Systems, Market Research and Corporate Finance. Mr. Meckler most recently was the Principal Executive Officer of QLT Inc.

Cocrystal Pharma, Inc. Files Amendment to its Certificate of Incorporation

On March 3, 2015, Cocrystal Pharma, Inc. filed an amendment to its Certificate of Incorporation with the Secretary of State of Delaware. This amendment increased the number of its authorized shares of common stock from 200,000,000 to 800,000,000. The amendment was effective upon filing. In accordance with the terms of the Certificate of Designation designating the Series A Preferred Stock and the Certificate of Incorporation designating the Series B Preferred Stock, immediately upon filing of the Certificate of Amendment to the company's Certificate of Incorporation, and without further action on the part of the holders, the Series A was converted into 340,760,802 shares of common stock and the Series B was converted into 205,083,086 shares of common stock.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
COCP:US $1.15 USD +0.0099

COCP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for COCP.
View Industry Companies

Industry Analysis


Industry Average

Valuation COCP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 13,929.9x
Price/Book 4.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 21,498.6x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact COCRYSTAL PHARMA INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at